New study shows promise for diphenyl ditelluride as anti-cancer drug

FHS
June 27, 2023
2:00 am

A new research paper was published in Oncotarget’s Volume 14 on June 21, 2023, entitled, “Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells.”

J&J heats up LAA closure competition with $400M Laminar buy

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Competition in the left atrial

November 30, 2023

Study shows significant drop in insulin costs after colorado caps prices

Diabetes affects millions of Americans, with 1.4 million new cases diagnosed each year. This chronic condition is one of the leading causes of death in

September 9, 2024

FDA grants RMAT designation to Poseida’s P-BCMA-ALLO1

P-BCMA-ALLO1 is licensed to Roche for the treatment of relapsed/refractory multiple myeloma. Credit: SkazovD/Shutterstock. Poseida Therapeutics has received the Regenerative Medicine Advanced Therapy (RMAT) designation

September 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.